| Segment information |
Segment information for year 2019
(Euro, in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
R&D
|
|
Fee-for-services
|
|
Inter-segment
elimination
|
|
Group
|
|
External revenue
|
|
€
|
834,901
|
|
€
|
10,084
|
|
|
|
|
€
|
844,985
|
|
Internal revenue
|
|
|
|
|
|
6,742
|
|
€
|
(6,742)
|
|
|
|
|
Other income
|
|
|
50,905
|
|
|
—
|
|
|
|
|
|
50,905
|
|
Revenues & other income
|
|
|
885,806
|
|
|
16,826
|
|
|
(6,742)
|
|
|
895,890
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment result
|
|
|
407,464
|
|
|
1,125
|
|
|
|
|
|
408,589
|
|
Unallocated expenses (1)
|
|
|
|
|
|
|
|
|
|
|
|
(38,297)
|
|
Operating income
|
|
|
|
|
|
|
|
|
|
|
|
370,292
|
|
Financial (expenses)/income
|
|
|
|
|
|
|
|
|
|
|
|
(220,233)
|
|
Result before tax
|
|
|
|
|
|
|
|
|
|
|
|
150,060
|
|
Income taxes
|
|
|
|
|
|
|
|
|
|
|
|
(214)
|
|
Net income
|
|
|
|
|
|
|
|
|
|
|
€
|
149,845
|
|
(1)
| |
The unallocated expenses of €38,297 thousand comprise warrant costs. |
Segment information for year 2018
(Euro, in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
R&D
|
|
Fee-for-services
|
|
Inter-segment
elimination
|
|
Group
|
|
External revenue
|
|
€
|
278,666
|
|
€
|
10,170
|
|
|
|
|
€
|
288,836
|
|
Internal revenue
|
|
|
|
|
|
8,508
|
|
€
|
(8,508)
|
|
|
|
|
Other income
|
|
|
29,000
|
|
|
9
|
|
|
|
|
|
29,009
|
|
Revenues & other income
|
|
|
307,666
|
|
|
18,687
|
|
|
(8,508)
|
|
|
317,845
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment result
|
|
|
(19,734)
|
|
|
1,751
|
|
|
|
|
|
(17,983)
|
|
Unallocated expenses (1)
|
|
|
|
|
|
|
|
|
|
|
|
(26,824)
|
|
Operating loss
|
|
|
|
|
|
|
|
|
|
|
|
(44,807)
|
|
Financial (expenses)/income
|
|
|
|
|
|
|
|
|
|
|
|
15,598
|
|
Result before tax
|
|
|
|
|
|
|
|
|
|
|
|
(29,209)
|
|
Income taxes
|
|
|
|
|
|
|
|
|
|
|
|
(50)
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
€
|
(29,259)
|
|
(1)
| |
The unallocated expenses of €26,824 thousand principally comprise of €26,757 thousand of warrant costs. |
Segment information for year 2017
(Euro, in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
R&D
|
|
Fee-for-services
|
|
Inter-segment
elimination
|
|
Group
|
|
External revenue
|
|
€
|
118,262
|
|
€
|
8,825
|
|
|
|
|
€
|
127,087
|
|
Internal revenue
|
|
|
|
|
|
5,104
|
|
€
|
(5,104)
|
|
|
|
|
Other income
|
|
|
28,815
|
|
|
15
|
|
|
|
|
|
28,830
|
|
Revenues & other income
|
|
|
147,077
|
|
|
13,945
|
|
|
(5,104)
|
|
|
155,918
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment result
|
|
|
(73,610)
|
|
|
86
|
|
|
|
|
|
(73,524)
|
|
Unallocated expenses (1)
|
|
|
|
|
|
|
|
|
|
|
|
(16,278)
|
|
Operating loss
|
|
|
|
|
|
|
|
|
|
|
|
(89,802)
|
|
Financial (expenses)/income
|
|
|
|
|
|
|
|
|
|
|
|
(25,705)
|
|
Result before tax
|
|
|
|
|
|
|
|
|
|
|
|
(115,507)
|
|
Income taxes
|
|
|
|
|
|
|
|
|
|
|
|
(198)
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
€
|
(115,704)
|
|
(1)
| |
The unallocated expenses of €16,278 thousand principally comprise of €16,536 thousand of warrant costs. |
|
| Summary of revenues by destination |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31,
|
|
|
|
2019
|
|
2018
|
|
2017
|
|
|
|
(Euro, in thousands)
|
|
North America
|
|
€
|
795,605
|
|
€
|
117,609
|
|
€
|
82,050
|
|
Europe
|
|
|
49,018
|
|
|
171,113
|
|
|
45,037
|
|
Asia Pacific
|
|
|
362
|
|
|
114
|
|
|
—
|
|
Total
|
|
€
|
844,985
|
|
€
|
288,836
|
|
€
|
127,087
|
|
| Summary of revenues by major customers |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31,
|
|
|
|
2019
|
|
2018
|
|
|
2017
|
|
Spilt up of revenues by major customers
|
|
(Euro, in
thousands)
|
|
%
|
|
(Euro, in
thousands)
|
|
%
|
|
(Euro, in
thousands)
|
|
%
|
|
Gilead:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America (1)
|
|
€
|
793,873
|
|
94%
|
|
€
|
116,640
|
|
40%
|
|
€
|
80,687
|
|
63%
|
|
Europe (1)
|
|
|
(4,570)
|
|
-1%
|
|
|
7,793
|
|
3%
|
|
|
|
|
|
|
AbbVie:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Europe
|
|
|
26,356
|
|
3%
|
|
|
89,936
|
|
31%
|
|
|
34,049
|
|
27%
|
|
Novartis:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Europe
|
|
|
19,177
|
|
2%
|
|
|
55,218
|
|
19%
|
|
|
|
|
|
|
Les Laboratoires Servier:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Europe
|
|
|
—
|
|
0%
|
|
|
9,000
|
|
3%
|
|
|
67
|
|
0%
|
|
Total revenues from major customers
|
|
€
|
834,836
|
|
99%
|
€
|
|
278,587
|
|
96%
|
|
|
114,804
|
|
90%
|
Following the contract amendment, the revenue recognized for filgotinib for the year ended December 31, 2019, included a negative catch-up effect on closing date of €245.9 million resulting from the decrease in the percentage of completion applied to previously received upfront and milestones for that program.
|